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CObjectives: To estimate a EQ-5D value set for Malaysia by using time
trade-off (TTO) and visual analogue scale (VAS) valuation methods.
Methods: TTO and VAS valuations were obtained from face-to-face
surveys of a convenience sample of patients, caregivers, and health
professionals conducted at nine government hospitals in 2004 and
2005. Forty-five EQ-5Dquestionnaire health stateswere valued, divided
into five sets of 15 health states. Analysiswas conducted by using linear
additive regression models applying N3 and D1 specifications. Model
selection was based on criteria of coefficient properties, statistical sig-
nificance, and goodness of fit. Results: One hundred fifty-two respon-
dents were interviewed, yielding 2174 TTO and 2265 VAS valuations.
Respondents found TTO valuations to be more difficult than VAS val- O
e no
g Sdn
al So
doi:10.1016/j.jval.2011.11.024ations, and there were more inconsistencies in TTO valuations. All
he independent variables in the models were statistically significant
nd consistent with expected signs and magnitude, except for the D1
pecification modeled on TTO valuations. The N3 model provided the
est fit for the VAS valuation data, with a mean absolute error of 0.032.
onclusion: This study provides a Malaysian EQ-5D questionnaire
alue set that can be used for cost-utility studies despite survey limi-
ations.
eywords: EQ-5D, health state preference, time trade-off, visual ana-
ogue scale.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Quality-adjusted life-years are a widely accepted measure of util-
ity used in health economic evaluation studies [1,2]. The EuroQol
EQ-5D questionnaire, a general measure of health status devel-
oped by the EuroQol group [3], is a frequently used instrument that
llows the measurement of quality-adjusted life-years. Using the
Q-5D questionnaire, the first population-based health preference
alue set was developed for the United Kingdom in 1997 [4].
Although the UK value set has been widely used in cost-utility
studies, studies have shown that valuation can be systematically
different between populations, possibly due to fundamental dif-
ferences in culture [5–7]. This divergence in health preferences
between countries has led to recommendations that call for na-
tional value sets to be developed for conducting cost-utility anal-
ysis [8].
Malaysia is a middle-income developing Southeast Asian
ountry. Because of its multiracial population with a Muslim ma-
ority, it is culturally different from the other Asian countries
here national EQ-5D value sets have been developed so far. It is
ebatable whether the value sets currently available can ade-
uately reflect the health preferences of Malaysians in particular
r Southeast Asians in general.
Conflicts of interest: The authors have indicated that they hav
* Address correspondence to:Adrian Goh, Azmi Burhani Consultin
Malaysia.
E-mail: adrian.goh@azmi-burhani.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.Therefore, our study sought to develop a value set for EQ-5D
health states by using preferences elicited from time trade-off
(TTO) and visual analogue scale (VAS) methods from a conve-
nience sample of the Malaysian population.
Methods
Data collection
The EQ-5D questionnaire descriptive systemmeasures health sta-
tus in five dimensions of mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. Each dimension has three
levels of severity, namely, 1) no problem, 2) some problem, and
extreme problem 3). The descriptive system contains a total of 243
theoretically possible combinations of EQ-5D questionnaire do-
mains and problem levels, referred to as health states.
This study analyzed previously elicited health state prefer-
ences to produce a Malaysian EQ-5D value set. Preferences were
elicited through convenience sampling from three categories of
respondents—patients undergoing dialysis, patients’ carers, and
dialysis center staff—in nine Ministry of Health (MoH) hospitals
throughout Peninsular Malaysia. Responses were elicited through
face-to-face interviews conducted in 2004 to 2005 by three trained
conflicts of interest with regard to the content of this article.
Bhd, 6-2, Jalan SS 7/16, Kelana Jaya, 47301 Petaling Jaya, Selangor,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Hospital. The health state preference data for this study were col-
lected as part of an economic study on erythropoietin use in the
MoH dialysis program [9].
The valuation process was similar to the method used in the
Measure and Valuation in Health study that first derived the UK
value set [4,10]. Forty-five health states were valued in the survey
by using ranking, VAS, and TTO elicitation methods. These were
the health states of “death” and “unconscious” as well as 43 of the
243 EQ-5D questionnaire health states.
During the survey, respondentswere taken through a four-step
valuation process, as illustrated in Appendix 1 in Supplemental
Materials found at doi:10.1016/j.jval.2011.11.024. They were first
asked to describe their own health state on the day of the inter-
view by filling the standard EQ-5D health assessment question-
naire. This comprised the EQ-5D questionnaire descriptive system
where the respondents selected, in multiple-choice fashions, one
of the three severity levels for each of the five health dimensions.
Respondents then proceeded to make a single mark on a 20-cm
long VAS, which ranged from a value of 100 for the “best imagin-
able health state” to 0 for the “worst imaginable health state.”
Upon completion of the own health rating exercise, respondents
were assigned one of five sets of health states to value. Each set
contained four common states (best health state, worst health
state, death, and unconscious), two very mild, three mild, three
moderate, and three severe health states following the approach
adopted by Shaw et al. [11], as shown inAppendix 2 in Supplemen-
tal Materials found at doi:10.1016/j.jval.2011.11.024.
First, respondents ranked the 15 health states in their set from
best to worst. They were permitted to place health states on an
equal rank if they so chose. Second, the respondentswere asked to
value the 15 states on a 20-cm longVAS. This formed the data used
for modeling the VAS value set. Third, in the TTO value elicitation
part, respondents valued 13 health states, with the best health
state 11111 and death excluded. 11111 and death were excluded
because these were the comparator states by which the respon-
dents performed the TTO valuation. Respondents were asked to
make a choice between living 10 years in a health state 11111 or in
another health state, followed by death at the end of 10 years. The
amount of life in 11111 was adjusted on a TTO prop until the
respondent felt that the two scenarios were indifferent. For states
considered worse than death, the scenario was altered to a choice
between immediate death or a number of years in a health state
followed by 10 years in health state 11111 followed by death. The
prop used in the above TTO valuation was a two-sided TTO valu-
ation board procured from Dr. Stephen Coons of The University of
Arizona, USA.
The study used two similar questionnaires in English and Ma-
lay languages for the study. The EQ-5D questionnaires obtained
from EuroQol were the Malay language version validated for Ma-
laysia and the English version validated for Singapore, a neighbor-
ing country with many historical, cultural, and demographic sim-
ilarities with Malaysia. The Singapore English version was used
because a Malaysian-validated English version was not available
at the time of the survey. Subsequent research has demonstrated
the reliability and validity of the EQ-5D questionnaire used in the
health preference elicitation survey [12].
Malaysia is a multiracial and multilingual country with Malay,
English, Mandarin, various Chinese dialects, and Indian languages
(particularly Tamil) used by substantial numbers of the population
in the Peninsular region of the country. The study team, however,
did not pursue translations in Chinese or Indian languages be-
cause of resource constraints. It was felt that questionnaires in
English and Malay would suffice to cover the vast majority of the
population in Peninsular Malaysia because most Malaysians are
fluent in either or both Malay and English because these are the
languages used in education, commerce, government, and publicdiscourse. Nevertheless, the few potential respondents who were
only monolingual speakers of Chinese or Indian languages were
not selected for the valuation elicitation survey. Those excluded
would typically be elderly Malaysians of Chinese or Indian ethnic
descent.
The original study that collected the health preference data
was approved by the Medical Research and Ethics Committee of
the MoH, Malaysia, and was funded by a research grant from the
MoH as part of a larger economic study on dialysis in MoH hospi-
tals. The funding from that project did not extend to the current
analysis, whichwas conducted on the authors’ own initiative. The
health preference data were used with permission from the MoH.
Data transformation
Health preference valuations of 0 to 100 on the VAS were rescaled
to 0 to 1, and valuations of other health states were rescaled
against health state 11111 and death as valued by the same re-
spondent.
TTO valuations were transformed to lie on the interval (1, 1).
States regarded as better thandeathwere calculated as t/10,where
t is the number of years in 11111 (equivalent to 10 years), whereas
states regarded as worse than death were calculated as t/10.
Analysis
Inconsistencies in respondent preference valuations were evalu-
ated in terms of the number of inconsistencies when using the
TTO and VAS scoring methods. Inconsistencies occurred where
respondents valued health states that are logically superior as
worse than inferior health states. A respondent’s entire set of val-
uations was excluded from analysis if 1) all health states were
valued the same; 2) fewer than five health states were valued; or 3)
death was valued higher than or equal to health state 11111. Val-
uations were not excluded on account of excessive inconsisten-
cies unlike in other studies.
Linear additive regression was used to demonstrate the rela-
tionship between the rescaled VAS and TTO with health dimen-
sions. Several model specifications were used in the modeling ex-
ercise. First, a main effects model was used, which consisted of a
constant and 10 variables that captured the movement from se-
verity 1 to 2 and from severity 2 to 3 for each of the five health
dimensions [5,6]. Second, the N3model from the original UK Mea-
sure and Valuation in Health study was used [4]. The N3 model
includes all the variables from themain effectsmodel and adds an
N3 interaction variable to capture any health state with a severe
(level 3) health state. Last, to compare themost appropriatemodel,
the analysis also employed the D1 valuation model from the
United States [11]. The model includes several interaction terms,
which are D1 (an ordinal variable capturing the number of dimen-
sions away from 11111 beyond the first and ranges from 0 to 4), I2
(an ordinal variable that captures the number of dimensions at
level 2 beyond the first), I3 (an ordinal variable that captures the
number of dimensions at level 3 beyond the first), as well as I2
squared and I3 squared.
The models were evaluated by criteria of 1) coefficient proper-
ties, 2) statistical significance, and 3) goodness of fit. The coeffi-
cients criterion evaluates the models by the signs of the coeffi-
cients and their magnitudes. All the main effects coefficients
should be negative, with larger negative values for level 3 coeffi-
cients relative to their level 2 counterparts. This reflects the fact
that any movement away from 11111 is a reduction in health and
anymovement to a severe problem (level 3) in a health dimension
ought to reduce quality of life more than would a move to a mod-
erate problem (level 2). Statistical significance was evaluated by
examining the significance of individual coefficients (t test P val-
ues) and the significance of models as a whole (F test P values).
Goodness of fit of models was evaluated by adjusted R2 and the
w
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ues. Last, the VASmodels were compared against the TTOmodels
on the basis of the quality of the underlying health state prefer-
ence used to generate them.
Results
Survey respondents
A total of 153 health preference valuation exercises were com-
pleted in face-to-face surveys conducted fromNovember 30, 2004,
to March 31, 2005, by three trained interviewers including one of
the authors (Faridah). Most of the respondents (79.1%) were pa-
tients undergoing dialysis, while 15.7% were MoH dialysis center
staff and 5.2% were patients’ carers (spouses, relatives, etc.) as
shown in Table 1. The average age of respondents was 41 years,
ith average own health state valued at 82 on the VAS on the day
f the survey.
Most respondents did not regard either the VAS valuation ex-
ercise or the TTO valuation exercise as being difficult although
more respondents found the TTO valuation to be more difficult
than the VAS valuation, as shown in Table 2. Only 16.3% of respon-
dents found the TTO valuation task difficult (11.1%) or very diffi-
cult (5.2%). The number of TTO valuation inconsistencies, how-
ever, was very high, with more than 65% of valuations having
more than two inconsistencies compared with 7.2% of VAS valu-
ations, as shown in Table 3. Out of the total 153 respondents who
provided valuations of EQ-5D questionnaire health states, VAS
valuations from two respondents were excluded because of the
respondents valuing death higher than or equal to health state
11111. TTO valuations from five respondents were excluded from
analysis, four for valuing all health states the same and one be-
cause fewer than five health states were valued. In total, 2265 VAS
valuations from 151 respondents and 2174 TTO valuations from
148 respondentswere used in themodeling of value sets, as shown
in Table 4.
Table 1 – Respondent characteristics.
Survey sa
Age (y), mean (SD) 41 (13
Males, n (%) 89 (58
Duration on dialysis (y), mean (SD) 5.72 (4.9
Hemodialysis (%) 100 (76
Own VAS score, mean (SD) 82 (13
Respondents, n (%) 153 (10
Patients undergoing dialysis 121 (79
Health-care personnel 24 (15
Caregivers 8 (5.2
VAS, visual analogue scale.
Table 2 – Difficulty of valuation task.
Difficulty of valuation n %
VAS rated as difficult 11 7.2
VAS rated as very difficult 1 0.7
TTO rated as difficult 17 11.1
TTO rated as very difficult 8 5.2TTO, time trade-off; VAS, visual analogue scale.Modeling analysis
Table 4 presents the parameter estimates and goodness-of-fit sta-
tistics for the final model specifications using VAS and TTO valu-
ation data. All the coefficients in the D1 and N3 models are of the
expected negative sign andmagnitude, with level 3 coefficients of
all dimensions larger than their level 2 equivalents. The only ex-
ceptions are the coefficients of anxiety/depression in the N3
model derived from the TTO valuation where the coefficient of
anxiety/depression level 2 (0.051) was greater than that of anxi-
ety/depression level 3 (0.043). Most of the individual coefficients
were highly statistically significant (P 0.05) except usual activity
level 2 and level 3, in the N3model of the TTO valuation. However,
all models were statistically significant as measured by the F-test
statistic.
It is noted that our model regression coefficient in the D1
model for death is 1.516 for the rescaled VAS and 1.972 for
TTO. We believe this to be an artifact of the model and that it
does not affect the utility calculation. For clarification, we had
based our D1 model on the Shaw et al. version [11], but we had
to make modifications because there were coefficients with in-
correct magnitudes and low t values. We modified the model by
removing all interaction terms except D1 and added a death
dummy variable (i.e., death  1 if the health state being valued
was 44444 and death  0 if otherwise). Despite this artifact, we
believe the model still works well.
The superior properties ofmodels derived fromVAS valuations
were reflected by the lower MAEs in the VASmodels (MAE of 0.033
and 0.032 in D1 and N3 models) compared with MAEs in the TTO
models (MAE of 0.051 and 0.049 in D1 and N3 models). There were
fewer large absolute errors (AEs  0.05 and  0.1) between the
actual health state valuations by respondents and the predicted
health state value from the VAS-basedmodels. In contrast tomost
value sets, none of the predicted or observed health states had
negative values (states worse than death), as shown in Table 5.
The adjusted R2 goodness-of-fit statistics of the VAS valuation
Table 3 – Valuation Inconsistency.
Number of inconsistencies VAS
valuation
TTO
valuation
n % n %
None 97 63.4 24 15.7
1 28 18.3 10 6.5
2 17 11.1 19 12.4
2 11 7.2 100 65.4
Total respondents 153 100 153 100
Modeling sample
VAS TTO
41.05 (13.7) 40.91 (13.5)
88 (58.3) 87 (58.8)
5.75 (4.9) 5.75 (4.9)
99 (82.5) 97 (82.9)
82.03 (13.5) 81.90 (13.6)
151 (100) 148 (100)
120 (79.5) 117 (79.1)
23 (15.2) 23 (15.5)
8 (5.3) 8 (5.4)mple
.6)
.2)
)
.3)
.4)
0)
.1)
.7)
)TTO, time trade-off; VAS, visual analogue scale.
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S88 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 8 5 – S 9 0models were higher than those from the TTO valuation models
with adjusted R2 in the range of 0.7 comparedwith 0.4, as shown in
able 4.
The “best model,” assessed from the criteria of coefficient
roperties, statistical significance, and goodness of fit, was the N3
odel derived from the VAS valuation. The N3 and the D1models
erived from the VAS valuationwere virtually identical in terms of
he three selection criteria. However, the N3 VASmodel has fewer
arge AEs (AE  0.1) between predicted and actual health states
ompared with the D1 VAS model, as shown in Table 4. The pre-
icted values of all 243 EQ-5D questionnaire health states are
hown in Appendix 3, and the calculation of health states using
his value set is shown in Appendix 4 in Supplemental Materials
ound at doi:10.1016/j.jval.2011.11.024.
Discussion
In this analysis, models derived from VAS valuations were supe-
rior to models developed from TTO valuations in terms of coeffi-
cient properties, statistical significance, and goodness of fit. Al-
though the N3 and D1models using VAS valuations were virtually
identical, theN3modelwasmarginally the bettermodel because it
had fewer large AEs (AEs  0.1) between the predicted and actual
ealth state values. Furthermore, the N3 VAS valuation model
inimizes the gap between health state 11111 and the next best
ealth state [13], as shown in Table 5 and Appendix 5 in Supple-
ental Materials found at doi:10.1016/j.jval.2011.11.024. There-
ore, value sets derived from the VAS valuation would appear to
erform better in the Malaysian setting. This is reinforced by the
uch lower rate of respondents reporting difficulty with the VAS
aluation task (Table 2) and the lower rate of inconsistent valua-
ions when the same respondents valued health states by VAS
ompared with TTO (Table 3). As can be expected, this Malaysian
Table 4 – Parameter estimates and goodness-of-fit statistic
Variable D1 model specifi
Rescaled
VAS
P value T
Constant 1.000 0.001
Mobility level 2 0.208 0.001 
Mobility level 3 0.330 0.001 
Self-care level 2 0.209 0.001 
Self-care level 3 0.292 0.001 
Usual activity level 2 0.203 0.001 
Usual activity level 3 0.295 0.001 
Pain/discomfort level 2 0.158 0.001 
Pain/discomfort level 3 0.277 0.001 
Anxiety/depression level 2 0.196 0.001 
Anxiety/depression level 3 0.239 0.001 
Dead 1.516 0.001 
Unconscious 1.463 0.001 
D1 0.129 0.001
N3
F statistic 538 0.001 12
R2 0.756
Adjusted R2 0.755
Mean absolute error 0.033
Number of absolute errors, n (%)
0.05 10 (24%) 21
0.1 3 (7%) 5 (
Number of respondents 151 14
Number of valuations 2265 217
TTO, time-trade off; VAS, visual analogue scale.alue set is different from the value sets developed in other coun- Uries, such as the original Measure and Valuation in Health study
rom UK as well as value sets from other Asian countries [4,5,14],
s shown in Figure 1.
The selection of a VAS-based value set goes against the current
reference for TTO-based valuations in Asia. Of the four value sets
ttempted so far in theAsian region, only theNewZealandvaluation
rom 2003 was derived from the VAS valuation while the two most
ecent valuations from South Korea from 2008 and 2009 were based
n TTO valuations [14–16]. EuroQol, however, has stated that “the
heoretical and empirical case for favoring one method of health
tate valuation over another is far from clear cut . . . for users the
hoice is between TTO and VAS. [17]” Notwithstanding the current
reference forTTOvaluations, there are somearguments against the
se of TTO valuations. Arnesen and Norhiem [18] argued that as-
umptions underlying TTO valuations are by nomeans certain. The
uthors questioned whether 1) TTO measures the willingness to
rade time for improved health; 2) TTO reveals true preferences; 3)
ife years are a suitable currency; and 4) quality of life is quantifiable.
From our own observations of Malaysian respondents, we en-
ountered resistance from some respondents who felt that the
ypothetical concept of trading away life years for improved
ealth was culturally unacceptable. Given the relatively strong
eligiosity ofmanyMalaysians, it would not be surprising for TTO-
ype valuations to encounter more resistance from respondents
omparedwith themorallymore neutral valuation on a VAS scale.
he other alternative valuation method is the standard gamble
SG). SGwas not used in the current study because TTO valuations
re more widely adopted for EQ-5D questionnaire valuation stud-
es [4–6,11,14,15]. A recent study indicates that SG might be pre-
erred to TTO for health preference elicitation in neighboring Sin-
apore [19]. Despite some similarities, however, there are
mportant differences in the demographic composition of Malay-
ia and Singapore that can affect the acceptability of SG questions.
final model specifications.
n N3 model specification
P value Rescaled
VAS
P value TTO P value
0.001 0.933 0.001 0.863 0.001
0.001 0.084 0.001 0.039 0.013
0.001 0.191 0.001 0.080 0.001
0.001 0.097 0.001 0.061 0.001
0.001 0.160 0.001 0.083 0.001
0.001 0.053 0.001 0.030 0.128
0.001 0.122 0.001 0.040 0.079
0.001 0.054 0.001 0.090 0.001
0.001 0.127 0.001 0.140 0.001
0.001 0.081 0.001 0.051 0.002
0.001 0.086 0.001 0.043 0.017
0.001 0.933 0.001 0.863 0.001
0.001 0.880 0.001 0.532 0.001
0.001
0.116 0.001 0.130 0.001
0.001 542 0.001 118 0.001
0.758 0.415
0.757 0.412
0.032 0.049
11 (26%) 17 (43%)
1 (2%) 5 (12%)
151 148
2265 2174s for
catio
TO
1.000
0.269
0.336
0.271
0.317
0.288
0.322
0.293
0.395
0.265
0.304
1.972
1.641
0.243
4
0.427
0.424
0.051
(50%)
12%)
8
4nlike Singapore,Malaysia has aMuslimmajority populationwho
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ence the suitability of SG as a choice method for Malaysia.
Another concern with the study is that it obtained valuations
froma respondent population by convenience sampling at dialysis
centers whereas EQ-5D questionnaire valuation studies have fol-
lowed the prescription of the US Public Health Service that the
“reference case” preferences are those from a representative sam-
ple of the general population with the justification that as the
ultimate payers of health care (whether through contributions to
health insurance schemes or as taxpayers who fund health sys-
tems) the general public’s preferences are the ones that count
[1,20].
There have been arguments that patients may provide higher
health state valuations because of strategic biases and that espe-
cially in the case of chronic conditions, patients’ coping mecha-
Table 5 – Predicted and observed health state values.
Health state Observed mean
VAS
VAS model’s predictio
D1 model AE N3 mode
11112 0.866 0.804 0.062 0.851
11113 0.753 0.761 0.008 0.731
11121 0.848 0.842 0.006 0.879
11122 0.768 0.775 0.007 0.798
11131 0.677 0.723 0.046 0.690
11133 0.511 0.613 0.102 0.604
11211 0.855 0.797 0.058 0.879
11312 0.587 0.639 0.051 0.614
12111 0.823 0.791 0.032 0.836
12121 0.787 0.762 0.024 0.782
12211 0.717 0.717 0.001 0.782
12222 0.643 0.622 0.021 0.647
12223 0.567 0.579 0.012 0.527
13212 0.530 0.567 0.037 0.522
13311 0.556 0.542 0.014 0.535
13332 0.268 0.327 0.059 0.326
21111 0.843 0.792 0.050 0.848
21133 0.464 0.534 0.070 0.519
21222 0.633 0.623 0.010 0.660
21232 0.485 0.503 0.019 0.471
21312 0.532 0.560 0.028 0.529
21323 0.522 0.488 0.034 0.471
22112 0.630 0.646 0.016 0.670
22121 0.687 0.684 0.003 0.697
22122 0.633 0.617 0.016 0.616
22222 0.524 0.543 0.019 0.563
22233 0.426 0.380 0.045 0.369
22323 0.374 0.408 0.034 0.374
22331 0.390 0.399 0.009 0.386
23232 0.367 0.340 0.027 0.310
23313 0.351 0.354 0.003 0.364
23321 0.412 0.435 0.023 0.397
32211 0.348 0.516 0.169 0.475
32223 0.373 0.378 0.004 0.336
32232 0.362 0.301 0.061 0.267
32313 0.325 0.315 0.011 0.321
32331 0.291 0.277 0.015 0.279
33212 0.260 0.366 0.106 0.331
33232 0.263 0.218 0.045 0.203
33321 0.264 0.313 0.048 0.290
33323 0.239 0.203 0.037 0.203
33333 0.122 0.083 0.039 0.130
MAE 0.033
AE, absolute error; MAE, mean absolute error; TTO, time trade-off; VAnisms may allow them to adapt to living with ill health [20,21].Empirically, the difference between population and patient valu-
ations is less clear, with some studies showing that patients tend
to value poor health states significantly higher than the general
public while other studies have not detected such systematic dif-
ferences [20,22,23].
Despite the preference for population-based valuations, it is
not absolutely clear that population preferences are superior to
patient-based preferences. Choices on whether population or pa-
tient perspectives should count are ultimately questions of polit-
ical theory and ethics. Recent research in the area suggests that
from an ethical perspective, there is good justification for prefer-
ring a patient perspective than a population-based one [21].
A particular weakness of this value set is that it is derived
from a small, nonrandom sample of respondents. Even com-
pared with the smallest sample sizes used to develop EQ-5D
Observed mean
TTO
TTO model’s prediction
AE D1 model AE N3 model AE
.015 0.813 0.735 0.078 0.812 0.001
.022 0.671 0.696 0.025 0.690 0.019
.031 0.732 0.707 0.024 0.773 0.041
.029 0.824 0.685 0.139 0.722 0.102
.013 0.530 0.605 0.074 0.593 0.063
.092 0.453 0.544 0.091 0.550 0.097
.024 0.785 0.712 0.073 0.833 0.048
.027 0.631 0.656 0.025 0.642 0.011
.012 0.785 0.729 0.055 0.802 0.017
.005 0.629 0.680 0.051 0.712 0.083
.066 0.773 0.684 0.089 0.772 0.001
.005 0.601 0.613 0.012 0.632 0.031
.040 0.570 0.574 0.004 0.510 0.061
.008 0.563 0.615 0.052 0.569 0.007
.022 0.483 0.604 0.120 0.610 0.127
.058 0.466 0.429 0.037 0.419 0.047
.006 0.787 0.731 0.056 0.824 0.037
.055 0.459 0.518 0.059 0.511 0.052
.027 0.587 0.615 0.027 0.653 0.066
.014 0.450 0.512 0.062 0.473 0.024
.003 0.586 0.630 0.045 0.603 0.017
.051 0.507 0.542 0.034 0.521 0.014
.040 0.696 0.681 0.014 0.712 0.016
.011 0.560 0.654 0.094 0.673 0.113
.017 0.657 0.632 0.026 0.622 0.035
.039 0.571 0.587 0.015 0.593 0.021
.057 0.577 0.445 0.131 0.420 0.156
.000 0.523 0.514 0.009 0.460 0.063
.003 0.492 0.472 0.020 0.453 0.039
.057 0.437 0.437 0.000 0.391 0.047
.013 0.547 0.517 0.030 0.528 0.019
.015 0.588 0.528 0.060 0.481 0.107
.128 0.467 0.591 0.124 0.562 0.096
.038 0.525 0.480 0.045 0.430 0.095
.095 0.363 0.416 0.054 0.372 0.009
.005 0.438 0.496 0.058 0.509 0.071
.012 0.506 0.405 0.101 0.412 0.094
.070 0.475 0.522 0.047 0.489 0.015
.060 0.422 0.370 0.052 0.349 0.072
.025 0.451 0.461 0.010 0.440 0.011
.036 0.433 0.400 0.034 0.397 0.036
.008 0.314 0.297 0.017 0.347 0.032
.032 0.051 0.049
sual analogue scale.n
l
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0questionnaire value sets elsewhere (300 in Spain, 309 in Neth-
S90 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 8 5 – S 9 0erlands [24]), the sample size of 153 in the current study is very
small by comparison. This, in part, was unavoidable because of
the resource constraints at the time of data collection. Neverthe-
less, the small sample was collected through face-to-face inter-
views by only three trained interviewers, which should reduce the
variability inherent in large population surveys. In spite of the
small sample size, the value sets presented here are statistically
valid and highly significant.
In conclusion, despite the limitations of the current study, until
such time as a larger valuation is conducted either in Malaysia or
in another country with closer cultural similarities to Malaysia,
the value set presented here should be considered for use in cost-
utility studies in Malaysia and other Southeast Asian countries.
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